Phase 2 Study of Neoadjuvant SAR444245 Plus Cemiplimab in HPV Related Oropharynx Squamous Cell Carcinoma
Status:
Not yet recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
To learn if SAR444245 given in combination with cemiplimab can help to kill cancer cells in
patients with HPV-related oropharynx cancer who are scheduled to have surgery to remove the
disease